Barclays
ANIK icon

Barclays’s Anika Therapeutics ANIK Stock Holding History

Barclays’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$767K Sell
52,928
-17,578
-25% -$204K ﹤0.01% 2916
2025
Q4 		$678K Buy
70,506
+38,432
+120% +$368K ﹤0.01% 3682
2025
Q3 		$301K Sell
32,074
-3,316
-9% -$31.7K ﹤0.01% 4096
2025
Q2 		$374K Buy
35,390
+7,379
+26% +$93.1K ﹤0.01% 3921
2025
Q1 		$421K Sell
28,011
-6,746
-19% -$112K ﹤0.01% 3631
2024
Q4 		$572K Buy
34,757
+2,093
+6% +$41.3K ﹤0.01% 3744
2024
Q3 		$807K Buy
32,664
+13,054
+67% +$338K ﹤0.01% 3500
2024
Q2 		$497K Sell
19,610
-8,244
-30% -$214K ﹤0.01% 3054
2024
Q1 		$707K Sell
27,854
-9,972
-26% -$241K ﹤0.01% 3366
2023
Q4 		$857K Buy
37,826
+11,061
+41% +$229K ﹤0.01% 3556
2023
Q3 		$499K Buy
26,765
+2,209
+9% +$45.8K ﹤0.01% 2818
2023
Q2 		$638K Buy
24,556
+3,988
+19% +$107K ﹤0.01% 2600
2023
Q1 		$591K Sell
20,568
-4,405
-18% -$131K ﹤0.01% 3150
2022
Q4 		$739K Sell
24,973
-340
-1% -$9.67K ﹤0.01% 3043
2022
Q3 		$602K Buy
25,313
+20,771
+457% +$478K ﹤0.01% 2585
2022
Q2 		$101K Sell
4,542
-7,105
-61% -$159K ﹤0.01% 3758
2022
Q1 		$293K Sell
11,647
-7,199
-38% -$219K ﹤0.01% 3210
2021
Q4 		$676K Buy
18,846
+6,193
+49% +$248K ﹤0.01% 3051
2021
Q3 		$538K Buy
12,653
+3,667
+41% +$151K ﹤0.01% 3152
2021
Q2 		$389K Sell
8,986
-18,551
-67% -$790K ﹤0.01% 3214
2021
Q1 		$1.12M Buy
27,537
+3,807
+16% +$144K ﹤0.01% 2700
2020
Q4 		$1.07M Sell
23,730
-5,645
-19% -$214K ﹤0.01% 2707
2020
Q3 		$1.04M Buy
29,375
+4,897
+20% +$177K ﹤0.01% 2657
2020
Q2 		$924K Buy
24,478
+10,339
+73% +$341K ﹤0.01% 2831
2020
Q1 		$409K Sell
14,139
-13,694
-49% -$554K ﹤0.01% 3745
2019
Q4 		$1.44M Sell
27,833
-7,332
-21% -$426K ﹤0.01% 3321
2019
Q3 		$1.93M Buy
35,165
+3,366
+11% +$173K ﹤0.01% 2913
2019
Q2 		$1.29M Buy
31,799
+15,092
+90% +$550K ﹤0.01% 3418
2019
Q1 		$506K Buy
16,707
+10,216
+157% +$350K ﹤0.01% 4104
2018
Q4 		$219K Sell
6,491
-14,216
-69% -$513K ﹤0.01% 4509
2018
Q3 		$872K Buy
20,707
+12,008
+138% +$474K ﹤0.01% 3762
2018
Q2 		$279K Sell
8,699
-20,394
-70% -$840K ﹤0.01% 4440
2018
Q1 		$1.45M Sell
29,093
-4,671
-14% -$264K ﹤0.01% 2799
2017
Q4 		$1.82M Buy
33,764
+4,482
+15% +$248K ﹤0.01% 2522
2017
Q3 		$1.7M Sell
29,282
-5,579
-16% -$292K ﹤0.01% 2512
2017
Q2 		$1.72M Buy
34,861
+15,559
+81% +$716K ﹤0.01% 2382
2017
Q1 		$839K Buy
19,302
+12,483
+183% +$596K ﹤0.01% 2888
2016
Q4 		$333K Sell
6,819
-18,769
-73% -$868K ﹤0.01% 3743
2016
Q3 		$1.22M Sell
25,588
-1,539
-6% -$76K ﹤0.01% 2436
2016
Q2 		$1.46M Sell
27,127
-13,091
-33% -$617K ﹤0.01% 2285
2016
Q1 		$1.77M Buy
40,218
+718
+2% +$29.1K ﹤0.01% 2029
2015
Q4 		$1.5M Buy
39,500
+20,723
+110% +$793K ﹤0.01% 2257
2015
Q3 		$582K Buy
18,777
+7,298
+64% +$254K ﹤0.01% 3224
2015
Q2 		$378K Buy
11,479
+11,044
+2,539% +$394K ﹤0.01% 3699
2015
Q1 		$18K Sell
435
-387
-47% -$15.6K ﹤0.01% 5881
2014
Q4 		$33K Sell
822
-789
-49% -$30.8K ﹤0.01% 6005
2014
Q3 		$58K Sell
1,611
-4,319
-73% -$187K ﹤0.01% 5758
2014
Q2 		$272K Buy
5,930
+2,629
+80% +$117K ﹤0.01% 4519
2014
Q1 		$135K Buy
3,301
+93
+3% +$3.46K ﹤0.01% 5166
2013
Q4 		$122K Sell
3,208
-848
-21% -$26.2K ﹤0.01% 5459
2013
Q3 		$93K Buy
4,056
+1,777
+78% +$39.9K ﹤0.01% 5668
2013
Q2 		$38K Buy
+2,279
New +$32.9K ﹤0.01% 6488

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Barclays's ANIK Position: Q1 2026 in Review

Barclays reduced its Anika Therapeutics (ANIK) stake by 25% in Q1 2026, selling an estimated $204K and leaving 52,928 shares worth $767K. The position accounts for ﹤0.01% of the portfolio, ranked #2916.

Barclays first reported a position in ANIK in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.93M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Barclays held 52,928 shares of Anika Therapeutics worth $767K as of Q1 2026.
  • Barclays sold 17,578 Anika Therapeutics shares in Q1 2026, an estimated $204K.
  • Anika Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2916 holding.
  • Barclays first reported a position in Anika Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Anika Therapeutics position peaked at $1.93M in Q3 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.